Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAS Wild Type mCRC”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Not applicableStudy completedNCT02322736
What this trial is testing

Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR

Who this might be right for
Metastatic Colorectal Cancer
Amgen 218
Large-scale testing (Phase 3)Not Yet RecruitingNCT07004413
What this trial is testing

Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients

Who this might be right for
Colorectal Cancer Metastatic
Charite University, Berlin, Germany 267
Large-scale testing (Phase 3)Not Yet RecruitingNCT06616259
What this trial is testing

First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study

Who this might be right for
Colorectal Cancer (CRC)CapecitabineCetuximab
Meng Qiu 452
Testing effectiveness (Phase 2)Looking for participantsNCT07724223
What this trial is testing

Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC

Who this might be right for
Metastatic Colorectal Cancer (CRC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 46
Testing effectiveness (Phase 2)Looking for participantsNCT07012954
What this trial is testing

CtDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

Who this might be right for
Colorectal Cancer Metastatic
Sun Yat-sen University 64
Early research (Phase 1)Looking for participantsNCT07543744
What this trial is testing

A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI

Who this might be right for
Metastatic Colorectal Cancer
R-Pharm 180
Testing effectiveness (Phase 2)Study completedNCT01927341
What this trial is testing

Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

Who this might be right for
Metastatic Colorectal Cancer
Pfizer 53
Large-scale testing (Phase 3)Study completedNCT01228734
What this trial is testing

A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients

Who this might be right for
Metastatic Colorectal Cancer
Merck KGaA, Darmstadt, Germany 553
Testing effectiveness (Phase 2)UnknownNCT05291156
What this trial is testing

CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Who this might be right for
Metastatic Colorectal Cancer
University of Campania Luigi Vanvitelli 173
Testing effectiveness (Phase 2)Study completedNCT00594984
What this trial is testing

Phase I/II Combination With Irinotecan- Erbitux

Who this might be right for
Metastatic Colorectal Cancer (MCRC)
Bristol-Myers Squibb 38
Large-scale testing (Phase 3)UnknownNCT05074966
What this trial is testing

The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts

Who this might be right for
Colo-rectal Cancer
Chinese Academy of Medical Sciences 314
Not applicableUnknownNCT03401957
What this trial is testing

The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment

Who this might be right for
Colorectal CancerDrug ResistanceMass Spectrometry+1 more
National Health Research Institutes, Taiwan 120
Not applicableStudy completedNCT04466267
What this trial is testing

The Molecular Mechanism of RAS Wild-type mCRC Resistance to Anti-EGFR-antibody

Who this might be right for
Colorectal Cancer
Sun Yat-sen University 40
Testing effectiveness (Phase 2)UnknownNCT03405272
What this trial is testing

Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC

Who this might be right for
Metastatic Colorectal Cancer
Sinocelltech Ltd. 110
Large-scale testing (Phase 3)Not Yet RecruitingNCT06959693
What this trial is testing

A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)

Who this might be right for
Metastatic Colorectal Cancer (CRC)
Sun Yat-sen University 590
Large-scale testing (Phase 3)Study completedNCT02394795
What this trial is testing

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC

Who this might be right for
Colorectal Cancer
Takeda 823
Testing effectiveness (Phase 2)Study completedNCT01008475
What this trial is testing

EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Merck KGaA, Darmstadt, Germany 232
Large-scale testing (Phase 3)Active Not RecruitingNCT04776655
What this trial is testing

Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB

Who this might be right for
Colorectal CancerMetastatic Colorectal CancerRAS Mutation
Azienda USL Reggio Emilia - IRCCS 280
Not applicableStudy completedNCT02624895
What this trial is testing

ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line

Who this might be right for
Metastatic Colorectal Cancer
Amgen 296
Large-scale testing (Phase 3)UnknownNCT03391934
What this trial is testing

Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Cinnagen 234
Next Page